NCT03559439 - CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions

B-cell MalignancyB-cell LymphomaB-Cell Acute Lymphoblastic Leukaemia

Interventions

BIOLOGICAL

CD19 CAR T

CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Tong Ren hospital, Shanghai